Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening, marketed by Abbott
Diagnostics, cancer, colorectal cancer, liquid biopsy, blood-based screening - Read more

Rinn Pharma & Biopharma, ArrayPatch collaborate to advance novel intradermal skin cancer microneedle therapy
Research collaboration, oncology, drug delivery, microneedle technology, preclinical - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

InnoCare Pharma's (fadeucravacitinib) meets primary endpoint in Ph3 trial for moderate-to-severe plaque psoriasis
Small molecule, autoimmune, TYK2 inhibitor, plaque psoriasis, oral therapy - Read more

GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) Ph3 trial meets primary endpoint in osteosarcoma, targeting B7-H3
Antibody-drug conjugate, cancer, ADC, osteosarcoma, B7-H3 target - Read more

Atea Pharmaceuticals' (bemnifosbuvir/ruzasvir) matches Gilead's Epclusa in Ph3 trial for hepatitis C
Small molecule, infectious disease, hepatitis C, direct-acting antiviral, fixed-dose combination, NS5B polymerase inhibitor - Read more

Altimmune's (pemvidutide) GLP-1/GIP dual agonist meets Ph2 primary endpoint in alcohol use disorder trial
Protein therapy, neurological, GLP-1/GIP dual agonist, alcohol use disorder, pemvidutide - Read more

Claris Biotherapeutics raises $118M Series B, advancing experimental eye drug for limbal stem cell deficiency
Ophthalmology, rare disease, cell therapy, clinical-stage - Read more

Oak Hill Bio plans $175M SPAC merger to advance Roche-licensed Angelman syndrome therapy
Rare disease, antisense oligonucleotide, neurological, clinical-stage - Read more

Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
Sleep apnea, small molecule, neuromuscular, clinical-stage - Read more

Promatix Biosciences awarded Innovate UK grant to advance first-in-class EGFR × EphA2 bispecific ADC
Oncology, antibody-drug conjugate, bispecific antibody, colorectal cancer, preclinical - Read more

KGK Science receives growth investment from Maxim Partners to expand clinical trial capacity
CRO, nutraceutical, clinical trials, regulatory services, consumer health - Read more

GSK to establish 300,000 sq ft flagship R&D centre at Cambridge Biomedical Campus, investing £400M ($531.6M)
R&D infrastructure, oncology, respiratory, strategic, major transaction - Read more

Schrödinger launches Bunsen AI co-scientist to computationally screen billions of drug compounds before lab testing
AI drug discovery, small molecule, operational, strategic - Read more

GSK launches three-year restructuring targeting $2.5B annual cost savings by 2029 to fund pipeline growth
Restructuring, oncology, cost reduction, operational, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Gossamer Bio, Chiesi end PAH drug collaboration, with Chiesi paying $5M termination fee
Licensing deal, rare disease, small molecule, milestone payments, royalties - Read more

MapLight Therapeutics' (betovumeline/fesoterodine) Ph2 once-daily dose misses primary endpoint in schizophrenia trial
Small molecule, neurological, muscarinic agonist, schizophrenia, M1/M4 receptor - Read more

Baxter International recalls antibiotic IV bags after cardboard particles found in solution, posing health risks
Small molecule, infectious disease, operational, product safety - Read more

FDA disputes Capricor Therapeutics' Phase 3 DMD trial success claims, sending shares down 65%
Cell therapy, rare disease, regulatory, financial - Read more

FDA deems Replimune's melanoma data "not interpretable," threatening RP1 approval ahead of advisory committee meeting
Oncolytic immunotherapy, oncology, regulatory, financial - Read more

Incyte drops phase 1 JAK2 inhibitor INCB160058 for myeloproliferative neoplasms, prioritizing next-generation replacements
Small molecule, rare disease, strategic, pipeline - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here